Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications

Richard E Katholi, Daniel M Couri, Richard E Katholi, Daniel M Couri

Abstract

Left ventricular hypertrophy is a maladaptive response to chronic pressure overload and an important risk factor for atrial fibrillation, diastolic heart failure, systolic heart failure, and sudden death in patients with hypertension. Since not all patients with hypertension develop left ventricular hypertrophy, there are clinical findings that should be kept in mind that may alert the physician to the presence of left ventricular hypertrophy so a more definitive evaluation can be performed using an echocardiogram or cardiovascular magnetic resonance. Controlling arterial pressure, sodium restriction, and weight loss independently facilitate the regression of left ventricular hypertrophy. Choice of antihypertensive agents may be important when treating a patient with hypertensive left ventricular hypertrophy. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers followed by calcium channel antagonists most rapidly facilitate the regression of left ventricular hypertrophy. With the regression of left ventricular hypertrophy, diastolic function and coronary flow reserve usually improve, and cardiovascular risk decreases.

References

    1. Sagie A, Benjamin EJ, Galderisi M, et al. Echocardiographic assessment of left ventricular structure and diastolic filling in elderly subjects with borderline isolated systolic hypertension (the Framingham Heart Study) American Journal of Cardiology. 1993;72(9):662–665.
    1. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension: the Framingham Heart Study. Circulation. 1994;90(1):179–185.
    1. Anversa P, Puntillo E, Olivetti G, et al. Cellular and mechanical adaptations in cardiac hypertrophy and its reversal. Cardiovascular Reviews and Reports. 1990;11(12):34–41.
    1. Johnson DB, Dell’Italia LJ. Cardiac hypertrophy and failure in hypertension. Current Opinion in Nephrology and Hypertension. 1996;5(2):186–191.
    1. Simpson TE, Dansky HM, Buttrick PM. Molecular genetic mechanisms of cardiac hypertrophy. Cardiovascular Risk Factors. 1995;5(2):93–108.
    1. Moser M. Initial workup of the hypertensive patient. In: Izzo JL, Black HR, Goodfriend TL, editors. Hypertensive Primer: The Essentials of High Blood Pressure. Philadelphia, Pa, USA: Williams and Wilkins; 1998. pp. 221–223.
    1. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. American Journal of Medicine. 1983;75(3 A):4–11.
    1. Casale PN, Devereux RB, Milner M. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Annals of Internal Medicine. 1986;105(2):173–178.
    1. Sugishita Y, Iida K, Fujieda K, Yukisada K. Decreased adrenergic response in hypertensive patients without left ventricular hypertrophy. Clinical Cardiology. 1994;17(2):71–76.
    1. Katholi RE, Ervin MR, Ginsburg G. Hypertensive heart disease syndrome in women in a cardiology practice. Comprehensive Therapy. 1997;23(8):508–513.
    1. Liao Y, Cooper RS, Mensah GA, McGee DL. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation. 1995;92(4):805–810.
    1. Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. Journal of the American Medical Association. 2004;292(23):2849–2859.
    1. Mogil JS, Sternberg WF, Kest B, Marek P, Liebeskind JC. Sex differences in the antagonism of swim stress-induced analgesia: effects of gonadectomy and estrogen replacement. Pain. 1993;53(1):17–25.
    1. Rosano GMC, Peters NS, Lefroy D, et al. 17-beta-estradiol therapy lessens angina in postmenopausal women with syndrome X. Journal of the American College of Cardiology. 1996;28(6):1500–1505.
    1. Mulé G, Nardi E, Cottone S, et al. Impact of the metabolic syndrome on total arterial compliance in essential hypertension patients. Journal of the Cardiometabolic Syndrome. 2007;2(2):84–90.
    1. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 1990;81(2):528–536.
    1. Sharp A, Tapp R, Francis DP, et al. Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. Journal of the American College of Cardiology. 2008;52(12):1015–1021.
    1. Grandi AM, Broggi R, Colombo S, et al. Left ventricular changes in isolated office hypertension: a blood pressure-matched comparison with normotension and sustained hypertension. Archives of Internal Medicine. 2001;161(22):2677–2681.
    1. Losito A, Fagugli RM, Zampi I, et al. Comparison of target organ damage in renovascular and essential hypertension. American Journal of Hypertension. 1996;9(11):1062–1067.
    1. Wu S, Polavarapu N, Stouffer GA. Left ventricular hypertrophy in patients with renal artery stenosis. American Journal of the Medical Sciences. 2006;332(6):334–338.
    1. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation. 1997;95(6):1471–1478.
    1. Frishman WH. Diagnosis and treatment of systolic heart failure in the elderly. American Journal of Geriatric Cardiology. 1998;7(6):10–55.
    1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney International. 1996;49(5):1379–1385.
    1. Katholi RE. Left ventricular hypertrophy: strategies for prevention and regression. Midwest Health. 2000;2:26–32.
    1. Ching GW, Franklyn JA, Stallard TJ, Daykin J, Sheppard MC, Gammage MD. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart. 1996;75(4):363–368.
    1. Singh JP, Johnston J, Sleight P, Bird R, Ryder K, Hart G. Left ventricular hypertrophy in hypertensive patients is associated with abnormal rate adaptation of QT interval. Journal of the American College of Cardiology. 1997;29(4):778–784.
    1. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete’s heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995;91(5):1596–1601.
    1. Maron BJ. Sudden death in young athletes. New England Journal of Medicine. 2003;349(11):1064–1075.
    1. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613–618.
    1. Douglas PS, O’Toole ML, Katz SE, Ginsburg GS, Hiller WDB, Laird RH. Left ventricular hypertrophy in athletes. American Journal of Cardiology. 1997;80(10):1384–1388.
    1. Pelliccia A, Culasso F, Di Paolo FM, Maron BJ. Physiologic left ventricular cavity dilatation in elite athletes. Annals of Internal Medicine. 1999;130(1):23–31.
    1. Reichek N, Helak J, Plappert T. Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results. Circulation. 1983;67(2):348–352.
    1. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension. 2002;39(3):750–755.
    1. Moon JCC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90(6):645–649.
    1. Olivotto I, Maron BJ, Appelbaum E, et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. American Journal of Cardiology. 2010;106(2):261–267.
    1. Puntmann VO, Jahnke C, Gebker R, et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. American Journal of Cardiology. 2010;106(7):1016–1022.
    1. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. Journal of Hypertension. 1995;13(10):1091–1095.
    1. Devereux RB, Agabiti-Rosei E, Dahlof B, et al. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. Journal of Hypertension, Supplement. 1996;14(2):S95–S102.
    1. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. Journal of the American Medical Association. 2004;292(19):2350–2356.
    1. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. Journal of the American Medical Association. 2004;292(19):2343–2349.
    1. Okin PM, Devereux RB, Harris KE, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Annals of Internal Medicine. 2007;147(5):311–319.
    1. Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE study. Circulation. 2007;116(7):700–705.
    1. Ferrara LA, De Simone G, Pasanisi F, Mancini M. Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension. 1984;6(5):755–759.
    1. Arroll B, Beaglehole R. Does physical activity lower blood pressure: a critical review of the clinical trials. Journal of Clinical Epidemiology. 1992;45(5):439–447.
    1. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003;107(1):68–73.
    1. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. Journal of the American Medical Association. 1996;275(19):1507–1513.
    1. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS) Circulation. 1995;91(3):698–706.
    1. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation. 1997;95(8):2007–2014.
    1. Tapp RJ, Sharp A, Stanton AV, et al. Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. Journal of the American College of Cardiology. 2010;55(17):1875–1881.
    1. Iriarte M, Caso R, Murga N, et al. Enalapril-induced regression of hypertensive left ventricular hypertrophy, regional ischemia, and microvascular angina. American Journal of Cardiology. 1995;75(12):850–852.
    1. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104(14):1615–1621.
    1. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530–537.
    1. Zhang X, Xie YW, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation. 1997;95(1):176–182.
    1. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. Journal of the American Medical Association. 2004;292(18):2217–2226.
    1. Frishman WH, Skolnick AE, Strom JA. Effects of calcium entry blockade on hypertension-induced left ventricular hypertrophy. Circulation. 1989;80(6):IV151–IV161.
    1. Vogt M, Strauer BE. Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. American Journal of Cardiology. 1995;76(13):24D–30D.
    1. Barone FC, Campbell WG, Jr., Nelson AH, Feuerstein GZ. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. Journal of Hypertension. 1998;16(6):871–884.
    1. Hansson L, Himmelmann A. Carvedilol in the treatment of hypertension—a review of the clinical data base. Scandinavian Cardiovascular Journal, Supplement. 1998;32(47):67–80.
    1. Xiaozhen H, Yun Z, Mei Z, Yu S. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Pressure. 2010;19(1):40–47.
    1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. Journal of the American Medical Association. 1996;275(20):1557–1562.
    1. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. Journal of the American College of Cardiology. 1996;28(2):506–514.
    1. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–1390.
    1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New England Journal of Medicine. 1996;334(21):1349–1355.
    1. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Journal of the American Medical Association. 2004;292(18):2227–2236.
    1. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. New England Journal of Medicine. 1994;330(26):1852–1857.
    1. Bayes-Genis A, Guindo J, Vinolas X, et al. Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. American Journal of Cardiology. 1995;76(13):54D–59D.
    1. Woods WT, Katholi RE, Urthaler F, James TN. Electrophysiological effects of magnesium on cells in the canine sinus node and false tendon. Circulation Research. 1979;44(2):182–188.
    1. Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. American Journal of Cardiology. 1995;76(13):18D–23D.
    1. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Archives of Internal Medicine. 1996;156(17):1969–1978.
    1. Williams B, Lacy PS. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. Journal of the American College of Cardiology. 2009;54(8):705–713.
    1. Indolfi C, Di Lorenzo E, Perrino C, et al. Hydroxymethylglutaryl coenzyme a reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation. 2002;106(16):2118–2124.
    1. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. European Journal of Clinical Investigation. 2007;37(9):681–691.
    1. Katholi RE, Rocha-Singh KJ, Goswami NJ, Sobotka PA. Renal nerves in the maintenance of hypertension: a potential therapeutic target. Current Hypertension Reports. 2010;12:196–204.
    1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet. 2009;373(9671):1275–1281.
    1. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. New England Journal of Medicine. 2009;361(9):932–934.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere